Panel of bar charts showing the mean change in A1C from baseline for pediatric and adult patients with type 2 diabetes. SURPASS-PEDS studied Mounjaro as add-on to metformin and/or basal insulin vs placebo over 30 weeks in pediatric patients 10 years of age and older with type 2 diabetes. The mean baseline A1C was 8.2%, 7.9%, 8.1%, and 8.0% for Mounjaro 5 mg, Mounjaro 10 mg, pooled Mounjaro (5 mg and 10 mg), and placebo, respectively. Patients in the Mounjaro 5 mg group (n=32) had a -1.9% change from baseline. Patients in the Mounjaro 10 mg group (n=33) had a -2.2% change from baseline. Patients in the pooled Mounjaro group (n=65) had a -2.0% change from baseline. Patients in the placebo group (n=34) had a -0.2 percent change from baseline.
SURPASS 1 through 5 evaluated the mean change in A1C from baseline in adult patients with type 2 diabetes. SURPASS-1 studied Mounjaro monotherapy vs placebo over 40 weeks. The mean baseline A1C was 8.0%, 7.9%, 7.9%, and 8.1% for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and placebo, respectively. Patients in the Mounjaro 5 mg group (n=32) had a -1.9% change from baseline. Patients in the Mounjaro 10 mg group (n=33) had a -2.2% change from baseline. Patients in the pooled Mounjaro group (n=65) had a -2.0% change from baseline. Patients in the placebo group (n=34) had a -0.2 percent change from baseline.
SURPASS-2 studied Mounjaro as an add-on to metformin vs Ozempic 1 mg over 40 weeks. The mean baseline A1C was 8.3% for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and Ozempic 1 mg. Patients taking Mounjaro 5 mg (n=470) had a -2.0% change from baseline. Patients taking Mounjaro 10 mg (n=469) had a -2.2% change from baseline. Patients taking Mounjaro 15 mg (n=469) had a -2.3% change from baseline. Patients taking Ozempic 1 mg (n=468) had a -1.9% change from baseline.
SURPASS-3 studied Mounjaro as an add-on to metformin plus or minus a sodium-glucose cotransporter-2 inhibitor vs Tresiba over 52 weeks. The mean baseline A1C was 8.2%, 8.2%, 8.2%, and 8.1% for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and Tresiba, respectively. Patients taking Mounjaro 5 mg (n=358) had a -1.9% change from baseline. Patients taking Mounjaro 10 mg (n=360) had a -2.0% change from baseline. Patients taking Mounjaro 15 mg (n=358) had a -2.1% change from baseline. Patients taking Tresiba (n=359) had a -1.3% change from baseline.
SURPASS-4 studied Mounjaro as an add-on to 1-3 oral antihyperglycemic medications (metformin, sulfonylurea, sodium-glucose cotransporter-2 inhibitor) vs insulin glargine over 52 weeks. The mean baseline A1C was 8.5%, 8.6%, 8.5%, and 8.5% for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and insulin glargine, respectively. Patients taking Mounjaro 5 mg (n=328) had a -2.1% change from baseline. Patients taking Mounjaro 10 mg (n=326) had a -2.3% change from baseline. Patients taking Mounjaro 15 mg (n=337) had a -2.4% change from baseline. Patients taking insulin glargine (n=998) had a -1.4% change from baseline.
SURPASS-5 studied Mounjaro as an add-on to basal insulin plus or minus metformin vs placebo over 40 weeks. The mean baseline A1C was 8.3%, 8.4%, 8.2%, and 8.4% for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and placebo, respectively. Patients taking Mounjaro 5 mg (n=116) had a -2.1% change from baseline. Patients taking Mounjaro 10 mg (n=118) had a -2.4% change from baseline. Patients taking Mounjaro 15 mg (n=118) had a -2.3% change from baseline.
Patients taking placebo (n=119) had a -0.9% change from baseline.